|
| 1） |
Labrie F, et al. Combination therapy with flutamide and castration（LHRH agonist or orchiectomy）in advanced prostate cancer:a marked improvement in response and survival. J Steroid Biochem. 1985;23:833-41. |
| 2） |
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer:an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet. 1995;346:265-9. |
| 3） |
Caubet JF, et al. Maximum androgen blockade in advanced prostate cancer:A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997;49:71-8. |
| 4） |
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer:an overview of the randomised trials. Lancet. 2000;355:1491-8. |
| 5） |
Eisenberger MA, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-42. |
| 6） |
Schmitt B, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer:a systematic review. Urology. 2001;57:727-32. |
| 7） |
Samson DJ, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361-76. |
| 8） |
Klotz L. Combined androgen blockade in prostate cancer:meta-analyses and associated issues. BJU Int. 2001;87（9）:806-13. |
| 9） |
Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone（LHRH）agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer:interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004;34（1）:20-8. |
| 10） |
Akaza H. Yoshida H, Takimoto Y, et al. Bicalutamide 80 mg in combination with an LHRHa versus LHRHa monotherapy in previously untreated advanced prostate cancer:A double-blind, placebo-controlled trial. ASCO abstract, 2005. |
新検索ページはこちら
ログイン
お問い合わせ
書誌情報
引用文献
